Cat. No.: HY-B0356G

Ciprofloxacin (GMP)

Name: Ciprofloxacin (GMP)
Brand: MedChemExpress
SKU: HY-B0356G
Availability: PreOrder

(Synonyms: Bay-09867 (GMP))

Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.

For research use only. We do not sell to patients.

CAS No.: 85721-33-1
Formula: C₁₇H₁₈FN₃O₃
Molecular Weight:331.34

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Ciprofloxacin (GMP) Chemical Structure

CAS No.: 85721-33-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Topoisomerase Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	135 μM Compound: 1	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
A-431	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A-431	IC₅₀	128 μM Compound: CFX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A549	IC₅₀	280 μM Compound: 1	Antitumor activity against human A549 cells after 5 days by MTT assay Antitumor activity against human A549 cells after 5 days by MTT assay	[PMID: 19595598]
A549	IC₅₀	100 μM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	IC₅₀	302 nM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
B-cell	IC₅₀	123 μM Compound: ciprofloxacin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
C8166	EC₅₀	100 μM Compound: CPX, ciprofloxacin	In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells. In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.	[PMID: 11020296]
CAPAN-1	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
CHO	CC₅₀	512 μM Compound: CPFX	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
CHO	IC₅₀	150 μM Compound: Ciprofloxacin	Cytotoxicity against CHO cells assessed as reduction in cell viability Cytotoxicity against CHO cells assessed as reduction in cell viability	[PMID: 30660827]
CHO	IC₅₀	150 μM Compound: CFX	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
CT26	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	202 μM Compound: 1	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
EJ	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	128 μM Compound: CFX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
HaCaT	IC₅₀	222.1 μM Compound: CP	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HBL-100	IC₅₀	10.28 μM Compound: C; Cip	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34319100]
HEK-293T	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
HeLa	EC₅₀	0.03 μM Compound: Ciprofloxacin	Inhibitory activity against HeLa cell Topoisomerase II Inhibitory activity against HeLa cell Topoisomerase II	10.1016/0960-894X(95)00160-U
HeLa	IC₅₀	290 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	120 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	800 μM Compound: 1	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
HeLa	IC₅₀	270 μM Compound: 1	Inhibition of human HeLa cell proliferation Inhibition of human HeLa cell proliferation	[PMID: 19595598]
HeLa	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay	[PMID: 27018907]
Hep 3B2	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HEp-2	CC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against Hep2 cell line Cytotoxicity against Hep2 cell line	[PMID: 16337789]
HEp-2	CC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep2 laryngeal carcinoma cell line Cytotoxicity against human Hep2 laryngeal carcinoma cell line	[PMID: 16337791]
HEp-2	CC₅₀	100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	100 μM Compound: CIP	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HepG2	IC₅₀	37.47 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in HepG2 cell line Cytotoxicity was determined for the compound in HepG2 cell line	[PMID: 14980680]
HepG2	CC₅₀	100 μM Compound: CIP	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	IC₅₀	0.5 mM Compound: CPX, B-H	Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay	[PMID: 21855181]
HepG2	IC₅₀	27 μM Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 28237557]
HepG2	CC₅₀	138.6 μg/mL Compound: CPX	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay	[PMID: 30067360]
HepG2	IC₅₀	128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay	[PMID: 27499455]
HepG2	IC₅₀	128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay	[PMID: 35231579]
HepG2	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay	[PMID: 38157595]
HL-60	IC₅₀	150 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability Cytotoxicity against human HL60 cells assessed as reduction in cell viability	[PMID: 30660827]
HL-60	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	302 nM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	150 μM Compound: CFX	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
K562	IC₅₀	150 μM Compound: 1	Inhibition of human K562 cell proliferation by sulphorodhamine B assay Inhibition of human K562 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
KB	IC₅₀	160 μM Compound: 1	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
KB	IC₅₀	128 μM Compound: CFX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
L02	IC₅₀	4.05 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	12.23 μM Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	64 μg/mL Compound: Cip	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38096652]
L1210	IC₅₀	150 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability	[PMID: 30660827]
L1210	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	IC₅₀	150 μM Compound: CFX	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
LoVo	IC₅₀	89 μM Compound: 1	Antitumor activity against human LoVo cells after 5 days by MTT assay Antitumor activity against human LoVo cells after 5 days by MTT assay	[PMID: 19595598]
MC3T3-E1	IC₅₀	120 μM Compound: 1	Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs	[PMID: 19595598]
MCF-10A	IC₅₀	300 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	[PMID: 24513049]
MCF7	IC₅₀	476 μM Compound: 1	Antitumor activity against human MCF7 cells after 5 days by MTT assay Antitumor activity against human MCF7 cells after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	199 μM Compound: 1	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	76 μM Compound: 1	Inhibition of human MCF7 cell proliferation after 5 days by MTT assay Inhibition of human MCF7 cell proliferation after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	100 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
MCF7	IC₅₀	8.85 μM Compound: C; Cip	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MCF7	IC₅₀	128 μM Compound: CFX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MG-63	IC₅₀	160 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	150 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	480 μM Compound: 1	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	181 μM Compound: Ciprofloxacin	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 24206766]
MRC5	IC₅₀	53.4 μg/mL Compound: CPF	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31431360]
MT4	CC₅₀	60 μM Compound: Ciprofloxacin	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 10397494]
NCI-H460	IC₅₀	60 μM Compound: 1	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
NIH3T3	IC₅₀	1000 μM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	200 μM Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay	[PMID: 23711920]
NIH3T3	IC₅₀	305.77 μg/mL Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	400 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
PBMC	IC₅₀	0.5 mM Compound: CPX, B-H	Cytotoxicity against human PBMC measured after overnight incubation by MTT assay Cytotoxicity against human PBMC measured after overnight incubation by MTT assay	[PMID: 21855181]
PC-3	IC₅₀	143 μM Compound: 1	Antitumor activity against human PC3 cells after 5 days by MTT assay Antitumor activity against human PC3 cells after 5 days by MTT assay	[PMID: 19595598]
PC-3	IC₅₀	101.4 μM Compound: CP	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SH-SY5Y	IC₅₀	0.5 mM Compound: CPX, B-H	Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay	[PMID: 21855181]
SK-MEL	IC₅₀	196 μM Compound: 1	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SK-MEL3	IC₅₀	128 μM Compound: CFX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SMMC-7721	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	100 μM Compound: Ciprofloxacin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
Splenocyte	IC₅₀	40 μM Compound: CIPRO	Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method	[PMID: 19908867]
SW-620	IC₅₀	200.4 μM Compound: CP	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW480	IC₅₀	128 μM Compound: 1	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]
SW480	IC₅₀	160.4 μM Compound: CP	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW480	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	128 μM Compound: CFX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
THP-1	IC₅₀	60.5 μM Compound: Ciprofloxacin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
U-373MG ATCC	IC₅₀	96 μM Compound: 1	Antitumor activity against human U373MG cells after 5 days by MTT assay Antitumor activity against human U373MG cells after 5 days by MTT assay	[PMID: 19595598]
V79	IC₅₀	380 μg/mL Compound: 40a	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	[PMID: 1469702]
V79	IC₅₀	200 μg/mL Compound: 21 Ciprofloxacin	Clonogenic cytotoxicity against Hamster V-79 cells Clonogenic cytotoxicity against Hamster V-79 cells	[PMID: 8145222]
V79	IC₅₀	320 μg/mL Compound: 22	Clonogenic cytotoxicity against Chinese hamster V-79 cells Clonogenic cytotoxicity against Chinese hamster V-79 cells	[PMID: 7473575]
V79	IC₅₀	1000 μM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
V79-4	IC₅₀	58.55 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in V79-4 cell line Cytotoxicity was determined for the compound in V79-4 cell line	[PMID: 14980680]
Vero	IC₅₀	188.5 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	CC₅₀	600.8 μM Compound: CPFX	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	IC₅₀	192 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24206766]
Vero	CC₅₀	128 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	128 μg/mL Compound: Ciprofloxacin	Cytotoxicity in African green monkey Vero cells Cytotoxicity in African green monkey Vero cells	[PMID: 31358466]
Vero	CC₅₀	512 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
WI-38	IC₅₀	100 μM Compound: Ciprofloxacin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]

In Vitro

Ciprofloxacin (GMP) (2.5-10 μg/mL; 24-72 h) preserves the stem cell-like spindle morphology of immortalized human dermal papilla cells, and concentrations of 5 and 10 μg/mL for 72 h significantly increase cell aggregation size and number^[1].
Ciprofloxacin (GMP) (10 μg/mL; 72 h) preserves CD133 stem cell marker expression and prevents increased procollagen type I fibroblast marker expression in immortalized human dermal papilla cells^[1].
Ciprofloxacin (GMP) (10 μg/mL; 24-72 h) prevents time-dependent loss of CD133, integrin β1, and ALDH1A1 stem cell markers and increases in procollagen type I fibroblast marker in immortalized human dermal papilla cells; concentrations of 2.5-10 μg/mL for 72 h modulate these markers in a dose-dependent manner^[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway in immortalized human dermal papilla cells in vitro in a dose-dependent manner, increasing activated Akt, inactivated GSK3β, and β-catenin levels^[1].
Ciprofloxacin (GMP) (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway and upregulates EMT transcription factors (ZEB1, Snail) in primary human dermal papilla cells in vitro in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

immortalized human dermal papilla cells (DPCs)
Concentration:

2.5-10 μg/mL
Incubation Time:

72 h
Result:

Increased levels of phosphorylated (activated) Akt (Ser 473), phosphorylated (inactivated) GSK3β (Ser 9), and β-catenin in a dose-dependent manner, with total Akt and GSK3β levels unchanged.\nSignificantly upregulated ZEB1, Snail, N-cadherin, vimentin, phosphorylated Erk (Thr 202/Tyr 204), Nanog, and Oct-4 in a dose-dependent manner, with minimal change in Slug levels.

Parmacokinetics

Species	Dose	Route	C_max	AUC	T_max
Rat^[2]	400 mg/kg	i.g.	9.6 mg/L	48.1 mg·h/L	1.5 h
Rat^[2]	800 mg/kg	i.g.	16.3 mg/L	97.2 mg·h/L	1.5 h
Rat^[2]	1200 mg/kg	i.g.	21.8 mg/L	143.1 mg·h/L	1.5 h

In Vivo

Ciprofloxacin GMP (400-1200 mg/kg; i.g.; daily; 7 days) induces dose-dependent chondrotoxicity in juvenile rats, with severe cartilage lesions, reduced cartilage thickness, and increased serum and cartilage concentrations observed at 800 and 1200 mg/kg, while no significant cartilage damage occurs at 400 mg/kg^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) (male, 4-week-old, drug-induced knee joint articular cartilage damage)^[2]
Dosage:

400 mg/kg; 800 mg/kg; 1200 mg/kg
Administration:

i.g.; daily; 7 days
Result:

Showed no obvious cartilage alterations at 400 mg/kg.
Caused severe cartilage lesions including matrix swelling and chondrocyte loss, and significantly decreased femoral condyle cartilage thickness compared to controls at 800 mg/kg or 1200 mg/kg.
Produced a maximum serum concentration (Cmax) of 9.6 mg/L, area under the plasma concentration-time curve (AUC₀-∞) of 48.1 mg·h·L^-1, and cartilage concentration of 7.4 μg·g^-1 at 400 mg/kg on day 1.
Produced a Cmax of 16.3 mg/L, AUC₀-∞ of 97.2 mg·h·L^-1, and cartilage concentration of 13.4 μg·g^-1 at 800 mg/kg on day 1.
Produced a Cmax of 21.8 mg/L, AUC₀-∞ of 143.1 mg·h·L^-1, and cartilage concentration of 20.3 μg·g^-1 at 1200 mg/kg on day 1.
Produced a Cmax of 9.4 mg/L and AUC₀-∞ of 51.1 mg·h·L^-1 at 400 mg/kg on day 6.
Produced a Cmax of 15.2 mg/L and AUC₀-∞ of 95.4 mg·h·L^-1 at 800 mg/kg on day 6.
Produced a Cmax of 23.7 mg/L and AUC₀-∞ of 148.8 mg·h·L^-1 at 1200 mg/kg on day 6.
Demonstrated similar Cmax and AUC₀-∞ values on day 1 and day 6, indicating no drug accumulation with repeated dosing.

Chemical Information

CAS No. 85721-33-1
Molecular Weight 331.34
Formula C₁₇H₁₈FN₃O₃
SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Synonyms

Bay-09867 (GMP)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Kiratipaiboon C, et al. Ciprofloxacin Improves the Stemness of Human Dermal Papilla Cells. Stem Cells Int. 2016;2016:5831276. [Content Brief]

[2]. Li P, et al. In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats[J]. Acta Pharmacologica Sinica, 2004, 25: 1262-1266.

[3]. Kamocki K, et al. Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies. Arch Oral Biol. 2015;60(8):1131-1137. [Content Brief]

[4]. Ilgin S, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-381. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ciprofloxacin (GMP)

All Topoisomerase Isoforms

All Akt Isoforms